ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RVNC Revance Therapeutics Inc

3.79
0.03 (0.80%)
Apr 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,598,010
Bid Price 3.71
Ask Price 3.88
News -
Day High 3.82

Low
3.625

52 Week Range

High
37.98

Day Low 3.625
Share Name Share Symbol Market Stock Type
Revance Therapeutics Inc RVNC NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.03 0.80% 3.79 18:58:35
Open Price Low Price High Price Close Price Previous Close
3.75 3.625 3.82 3.79 3.76
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
12,469 1,598,010 US$ 3.75 US$ 5,985,840 - 3.625 - 37.98
Last Trade Type Quantity Price Currency
16:47:55 formt 200 US$ 3.79 USD

Revance Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
335.21M 88.21M - 234.04M -323.99M -3.67 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Revance Therapeutics News

Date Time Source News Article
4/12/202407:00Business WireRevance to Present New DAXXIFY® Data at the American Academy..
3/27/202415:05Business WireRevance Reports Inducement Grants Under Nasdaq Listing Rule..
3/08/202415:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
3/05/202416:08Edgar (US Regulatory)Form 8-K - Current report
3/05/202416:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
3/04/202416:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
3/04/202416:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
3/04/202415:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
3/04/202415:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
3/04/202408:25Business WireRevance Announces Pricing of $100.0 Million Public Offering..
3/04/202405:39Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
3/04/202405:37Business WireRevance Announces Proposed Public Offering of Common Stock
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RVNC Message Board. Create One! See More Posts on RVNC Message Board See More Message Board Posts

Historical RVNC Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week4.454.533.6254.011,918,478-0.66-14.83%
1 Month5.105.423.6254.451,472,784-1.31-25.69%
3 Months5.817.563.6255.491,794,658-2.02-34.77%
6 Months9.149.7453.6256.481,723,891-5.35-58.53%
1 Year30.0437.983.62513.681,668,938-26.25-87.38%
3 Years27.0537.983.62518.621,205,998-23.26-85.99%
5 Years13.2537.983.62519.19942,900-9.46-71.40%

Revance Therapeutics Description

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products.

Your Recent History

Delayed Upgrade Clock